ISSN: 1308-5727 | E-ISSN: 1308-5735
Volume : Issue : Year : 2022

Abstracting & Indexing
Turkish Society for Pediatric Endocrinology and Diabetes
The Effect of Growth Hormone Therapy on Cardiac Outcomes in Noonan Syndrome: Long Term Follow-up Results [J Clin Res Pediatr Endocrinol]
J Clin Res Pediatr Endocrinol. Ahead of Print: JCRPE-35119 | DOI: 10.4274/jcrpe.galenos.2022.2022-12-13

The Effect of Growth Hormone Therapy on Cardiac Outcomes in Noonan Syndrome: Long Term Follow-up Results

Sirmen Kizilcan Cetin1, Mehmet Gokhan Ramoglu2, Zeynep Sİklar1, Elif Ozsu1, Zehra Aycan1, Hasan Ercan Tutar2, Merih Berberoglu1
1Department of Pediatric Endocrinology, School of Medicine, Ankara University, Ankara, Turkey
2Department of Pediatric Cardiology, School of Medicine, Ankara University, Ankara, Turkey

INTRODUCTION: Cardiac involvement is common in Noonan Syndrome (NS). Concerns have been raised regarding the effect of recombinant growth hormone (rGH) use on ventricular wall thickness and a possible increased risk of cardiac side effects. This study aimed to show the effect of rGH on the development of hypertrophic cardiomyopathy and other cardiac findings in NS.
METHODS: The subjects who were under the age of 18 and diagnosed with NS (according to the Van der Burgt criteria) were included. Patients were divided into two groups according to those receiving rGH or not at the time of obtaining cardiac measurements. Before and after the treatment, electrocardiographic and echocardiographic (ECHO) assessments included the interventricular septal thickness, left ventricular internal diameter, and left ventricular posterior thickness, expressing the findings as Z scores.
RESULTS: Twenty-four NS subjects (16 boys, eight girls) were included. At the beginning of the follow up, all were with a height SDS of-2.56±0.94 (data by Neyzi et al.). Sixteen were on rGH. The mean rGH treatment duration was 8.3±3.8 years, and the mean dose was 0.22±0.04 mg/kg/week. The final height was 169±8.2 cm, and 10 of 11 patients who reached the final height received rGH.There was no difference between the rGH and non-rGH groups in terms of ECHO parameters pre-and post-treatment.
DISCUSSION AND CONCLUSION: In this cohort, there was no change in ECHO parameters on rGH and during follow-up. These results suggest that rGH is safe in NS patients with cardiac pathology under close follow-up.

Keywords: Recombinant growth hormone therapy, Noonan syndrome, hypertrophic cardiomyopathy, left ventricular dimension

Corresponding Author: Sirmen Kizilcan Cetin, Türkiye
Manuscript Language: English
LookUs & Online Makale